Methylation profiling

Dataset Information

0

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences [HumanMethylationEPICv2]


ABSTRACT: In the WSG-ADAPT trial (NCT01779206), HR+/HER2-EBC patients underwent pre-operative short-term endocrine therapy (pET). Treatment response was determined by immunohistochemical in-situ labeling of cycling cells (G1 to M-phase) with Ki67 before and after pET. We performed Infinium MethylationEPICv2-based DNA methylation analysis post-pET in a validation cohort2 (n=176, unmatched). Predictive indices of endocrine resistance under both treatments were calculated as described in medRxiv 2023.11.13.23298466; doi: https://doi.org/10.1101/2023.11.13.23298466

ORGANISM(S): Homo sapiens

PROVIDER: GSE274415 | GEO | 2025/07/17

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2025-07-17 | GSE261142 | GEO
2021-01-04 | GSE164159 | GEO
| PRJEB42332 | ENA
2023-01-23 | GSE198835 | GEO
2018-03-01 | E-MTAB-6411 | biostudies-arrayexpress
2025-06-12 | GSE292202 | GEO
| EGAD00001011301 | EGA
2025-04-09 | GSE293850 | GEO
| PRJNA1085380 | ENA
2022-05-27 | GSE181036 | GEO